Literature DB >> 17360600

Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.

Herbert Y Meltzer1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17360600      PMCID： PMC1805573          DOI： 10.1073/pnas.0700090104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  25 in total

1.  Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?

Authors:  Herbert Y Meltzer
Journal:  Int J Neuropsychopharmacol       Date:  2005-03-21       Impact factor: 5.176

2.  Clozapine-induced weight gain: prevalence and clinical relevance.

Authors:  R Leadbetter; M Shutty; D Pavalonis; V Vieweg; P Higgins; M Downs
Journal:  Am J Psychiatry       Date:  1992-01       Impact factor: 18.112

3.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Authors:  H Y Meltzer; S Matsubara; J C Lee
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

4.  Clozapine-induced weight gain predicts improvement in psychopathology.

Authors:  Herbert Y Meltzer; Edward Perry; Karuna Jayathilake
Journal:  Schizophr Res       Date:  2003-01-01       Impact factor: 4.939

5.  The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.

Authors:  Michael Poyurovsky; Artashes Pashinian; Aya Levi; Ronit Weizman; Abraham Weizman
Journal:  Int Clin Psychopharmacol       Date:  2005-03       Impact factor: 1.659

6.  H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

Authors:  Wesley K Kroeze; Sandra J Hufeisen; Beth A Popadak; Sean M Renock; SeAnna Steinberg; Paul Ernsberger; Karu Jayathilake; Herbert Y Meltzer; Bryan L Roth
Journal:  Neuropsychopharmacology       Date:  2003-03       Impact factor: 7.853

Review 7.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Authors:  Neil D Woodward; Scot E Purdon; Herbert Y Meltzer; David H Zald
Journal:  Int J Neuropsychopharmacol       Date:  2005-03-23       Impact factor: 5.176

8.  Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.

Authors:  Bruce J Kinon; Christopher J Kaiser; Saeed Ahmed; Matthew D Rotelli; Sara Kollack-Walker
Journal:  J Clin Psychopharmacol       Date:  2005-06       Impact factor: 3.153

Review 9.  Treatment of psychosis in Parkinson's disease: safety considerations.

Authors:  Hubert H Fernandez; Martha E Trieschmann; Joseph H Friedman
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.

Authors:  Sonja Menghin; Heinz H Pertz; Kai Kramer; Roland Seifert; Walter Schunack; Sigurd Elz
Journal:  J Med Chem       Date:  2003-12-04       Impact factor: 7.446
View more
  4 in total

Review 1.  Atypical antipsychotics and diabetic ketoacidosis: a review.

Authors:  Melanie D Guenette; Margaret Hahn; Tony A Cohn; Celine Teo; Gary J Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

Review 2.  Adverse effects of clozapine in older patients: epidemiology, prevention and management.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

3.  Disconnected and Hyperactive: A Replication of Sensorimotor Cortex Abnormalities in Patients With Schizophrenia During Proactive Response Inhibition.

Authors:  Christopher J Wertz; Faith M Hanlon; Nicholas A Shaff; Andrew B Dodd; Juan Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Ronald A Yeo; Jingyu Liu; Vince Calhoun; Andrew R Mayer
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

Review 4.  Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.

Authors:  Joseph T Coyle; Darrick Balu; Michael Benneyworth; Alo Basu; Alexander Roseman
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.